Global pharmaceutical companies are accelerating investments in China's biotech sector, seeking to replenish drug pipelines and capture valuation growth amid a surge in domestic innovation.
Speakers at the recently concluded Global Health Summit highlighted the strategic shift, noting that foreign capital is increasingly flowing into Chinese biotech firms to tap into their rapid development capabilities.
Domestically developed novel drugs accounted for more than 80% of market approvals in China during the first six months of 2026, marking a substantial acceleration in the country's pharmaceutical innovation capabilities.
According to Citic Securities, these foreign investments are critical for Chinese companies to scale and compete on the global stage.
The move reflects a broader industry trend as major pharmaceutical firms face expiring patents on lucrative drugs, creating an urgent need to acquire or partner with innovative biotech firms.
This repricing of Chinese biotech assets comes as the sector demonstrates significant maturation.
Domestically developed novel drugs accounted for more than 80% of market approvals in China during the first six months of 2026, marking a substantial acceleration in the country's pharmaceutical innovation capabilities.
The influx of foreign interest suggests that Chinese biotech is no longer viewed solely as a manufacturing hub but as a source of proprietary innovation.